BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sonesitatug vedotin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sonesitatug vedotin\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07069712-11152@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20271109
DTEND;VALUE=DATE:20271110
SUMMARY:Sonesitatug vedotin: Phase 2 readout est. (NCT07069712)
DESCRIPTION:Sonesitatug vedotin\, phase 2.\nStudy: A Study of Novel Agents 
 or Combinations as Perioperative Treatment in Participants With Locally Ad
 vanced Resectable Gastroesophageal Adenocarcinoma\nEstimated primary compl
 etion: 9 November 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sonesitatug-vedotin#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07069712
URL:https://assetmemo.bio/drug/sonesitatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05702229-11152@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Sonesitatug vedotin: Phase 2 readout est. (NCT05702229)
DESCRIPTION:Sonesitatug vedotin\, phase 2\, Gastric Cancer.\nStudy: Novel C
 ombinations in Participants With Locally Advanced Unresectable or Metastat
 ic Gastric or Gastroesophageal Junction Adenocarcinoma\nEstimated primary 
 completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/sonesitatug-vedotin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05702229
URL:https://assetmemo.bio/drug/sonesitatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06630130-11152@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Sonesitatug vedotin: Phase 2 readout est. (NCT06630130)
DESCRIPTION:Sonesitatug vedotin\, phase 2\, Gastric Cancer.\nStudy: Periope
 rative Therapies in Locally Advanced Unresectable Gastric Cancer\nEstimate
 d primary completion: 30 October 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/sonesitatug-vedotin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06630130
URL:https://assetmemo.bio/drug/sonesitatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431281-11152@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20290816
DTEND;VALUE=DATE:20290817
SUMMARY:Sonesitatug vedotin: Phase 3 readout est. (NCT07431281)
DESCRIPTION:Sonesitatug vedotin\, phase 3\, Gastric Cancer.\nStudy: Sonesit
 atug Vedotin in Combination With Capecitabine With or Without Rilvegostomi
 g in Participants With Advanced or Metastatic Gastric\, Gastroesophageal J
 unction\, or Esophageal Adenocarcinoma Expressing Claudin18.2\nEstimated p
 rimary completion: 16 August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sonesitatug-vedotin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07431281
URL:https://assetmemo.bio/drug/sonesitatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
